MCTA Investors Pursue Charming Medical Securities Fraud Lawsuit with Schall Law Firm.
ByAinvest
Monday, Feb 9, 2026 4:04 pm ET1min read
MCTA--
Charming Medical Limited (MCTA) investors have an opportunity to lead a securities fraud lawsuit with the Schall Law Firm. The class action lawsuit alleges violations of the Securities Exchange Act of 1934 and Rule 10b-5. Investors who purchased MCTA securities between October 21, 2025, and November 12, 2025, are encouraged to contact the firm by February 17, 2026. The lawsuit claims that the company made false and misleading statements to the market, causing investors to suffer damages.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet